Table 3.

Subgroup analyses of all-cause mortality.

Subgroups	Total (N = 4886)
	Nirmatrelvir-ritonavir (N = 1462)				Molnupiravir (N = 3424)				ARR (95% CI) (%)	Adjusted HR (95% CI)a	p-value for interaction
	Events	Rate (%)	Follow-up time (days)	Incidence rate (per 10,000 person days)	Events	Rate (%)	Follow-up time (days)	Incidence rate (per 10,000 person days)
All-cause mortality
Age, years											0.127
<70	6	2.24	23,828	2.52 (0.92, 5.48)	14	2.03	61,289	2.28 (1.25, 3.83)	−0.21 (0.09, 3.22)	NAb
≥70	68	5.70	103,219	6.59 (5.12, 8.35)	259	9.48	229,767	11.27 (9.94, 12.73)	3.78 (1.62, 6.12)	0.566 (0.401–0.798)
Sex											0.227
Male	41	6.02	58,868	6.96 (5.00, 9.45)	137	8.59	135,116	10.14 (8.51, 11.99)	2.57 (0.32, 4.83)	0.873 (0.468–1.631)
Female	33	4.23	68,179	4.84 (3.33, 6.80)	136	7.43	155,940	8.72 (7.32, 10.32)	3.20 (1.35, 5.06)	0.571 (0.265–1.229)
CCI											0.894
≤5	35	3.88	79,095	4.43 (3.08, 6.15)	115	5.86	169,545	6.78 (5.60, 8.14)	1.98 (0.35, 3.61)	0.614 (0.321–1.174)
>5	39	6.96	47,952	8.13 (5.78, 11.12)	158	10.81	121,511	13.00 (11.05, 15.20)	3.85 (1.21, 6.49)	0.772 (0.402–1.482)
COVID-19 vaccination status											0.326
0–1 dose	15	8.88	14,411	10.41 (5.83, 17.17)	62	15.20	33,051	18.76 (14.38, 24.05)	6.32 (0.80, 11.85)	NAb
≥2 doses	59	4.56	112,636	5.24 (3.99, 6.76)	211	7.00	258,005	8.18 (7.11, 9.36)	2.44 (0.98, 3.89)	0.549 (0.372–0.81)

HR, Hazard ratio; CI, Confidence interval; CCI, Charlson Comorbidity Index.

^aHazard ratios were obtained from stratified Cox proportional hazard regression adjusted by sex, age, Charlson Comorbidity Index, vaccination status, hospitalisation, eGFR, renal replacement therapy, pre-existing comorbidities and medication use within 90 days at baseline.

^bNot applicable due to insufficient events observed.